Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock

Holger Thiele, MD
Uwe Zeymer, MD; Franz-Josef Neumann, MD; Miroslaw Ferenc, MD; Hans-Georg Olbrich, MD; Jörg Hausleiter, MD; Gert Richardt, MD; Marcus Hennersdorf, MD; Klaus Empen, MD; Georg Fuernau, MD; Steffen Desch, MD; Ingo Eitel, MD; Rainer Hambrecht, MD; Jörg Fuhrmann, MD; Michael Böhm, MD; Henning Ebelt, MD; Steffen Schneider, PhD; Gerhard Schuler, MD; Karl Werdan, MD

on behalf of the **IABP-SHOCK II Trial** Investigators

University of Leipzig – Heart Center

Disclosures

Funding:
German Research Foundation
German Heart Research Foundation
German Cardiac Society
Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte
University of Leipzig – Heart Center
Unrestricted grant by:
Maquet Cardiopulmonary AG, Hirrlingen, Germany
Teleflex Medical, Everett, MA, USA

Potential Conflict of Interest:

Research Funding:

Terumo, Lilly, Maquet Cardiovascular, Teleflex Medical

Consulting:

Maquet Cardiovascular, Lilly

Speaker Honoraria:

Lilly, Astra Zeneca, Daiichi Sankyo, Boehringer Ingelheim, Maquet Cardiovascular, Medicines Company

IABP in Cardiogenic Shock

IABP SHOCK II RANDOMIZED CLINICAL TRIAL

History:

1962 Animal studies

Moulopoulos et al. Am Heart J 1962;63:669-675

1968 First clinical description in shock

Kantrowitz et al. JAMA 1968;203:135-140

1973 Hemodynamic effects in shock, Mortality unchanged

Scheidt et al. NEJM 1973;288:979-984

> 40 years > 1 Million patients treated, low complication rate, Benchmark registry

Ferguson et al. JACC 2001;38:1456-1462

Guidelines

IABP SHOCK II
RANDOMIZED CLINICAL TRIAL

IABP in AMI complicated by cardiogenic shock

ESC

EUROPEAN SOCIETY OF CARDIOLOGY®

Class IC

ACC/AHA

American Heart Association

AMERICAN COLLEGE OF CARDIOLOGY

Class IB

Van de Werf et al. Eur Heart J 2008;29:2909-2945
Wijns et al. Eur Heart J 2010;31:2501-2555
Antman et al. Circulation 2004;110:82-292

Background

Mortality IABP vs no IABP - Metaanalysis



Sjauw et al. Eur Heart J 2009;30:459-468

Background

IABP-Use in Cardiogenic Shock



Thiele et al. Eur Heart J 2010,31:1828-1835

Methods

Study Sites and Organisation



DSMB:

Kurt Huber
Ferenc Follath
Bernhard Maisch
Johannes Haerting

Steering committee:

Holger Thiele
Karl Werdan
Uwe Zeymer
Gerhard Schuler

Support + Patronage:

DEUTSCHE GESELLSCHAFT FÜR KARDIOLOGIE - HERZ- UND KREISLAUFFORSCHUNG e.V.
GERMAN CARDIAC SOCIETY

Deutsche Herzstiftung

ALKK Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte e.V.

DFG Deutsche Forschungsgemeinschaft

Methods

IABP-Shock-II Trial – Timelines



Statistical Methodology

IABP SHOCK II RANDOMIZED CLINICAL TRIAL

Sample Size

– Estimated 12% absolute difference in survival rates
– Sequential statistical design with 2 interim analyses (33% and 66% of patients)
– Significance level 0.0005 at 1st or 0.014 at 2nd interim analysis.
Final analysis at α-level 0.044 → 564 patients
– To compensate losses in follow-up and putative center effect → 600 patients

Primary Study Endpoint:

30-day all-cause mortality

Secondary Study Endpoints:

- Hemodynamic parameters (mean BP, heart rate pre and post revascularization)
- Serum-lactate (every 8 h for 48 h)
- SAPS-2 Score
- Serial creatinine-level and creatinine-clearance (Cockcroft-Gault-formula)
- Inflammatory reaction (CRP)

Process of care

- Time until hemodynamic stabilization
- Catecholamine dose and duration
- Requirement for LVAD-implantation or HTx
- Requirement for renal replacement therapy
- Length of ICU-stay
- Length of mechanical ventilation
- Mortality after 6 and 12 months

Thiele et al. Am Heart J 2012;163:938-45

Results

Trial Flow and Treatment

IABP SHOCK II RANDOMIZED CLINICAL TRIAL



Results

Patient Characteristics

IABP SHOCK II RANDOMIZED CLINICAL TRIAL

	IABP (n=301)	Control (n=299)
Age (years); median (IQR)	70 (58-78)	69 (58-76)
Male sex; n (%)	202 (67.1)	211 (70.6)
Current Smoking; n/total (%)	96/295 (32.5)	108/299 (36.1)
Hypertension; n/total (%)	213/296 (72.0)	199/299 (66.6)
Hypercholesterolemia; n/total (%)	122/295 (41.4)	105/299 (35.1)
Diabetes mellitus; n/total (%)	105/297 (35.4)	90/299 (30.1)
Prior myocardial infarction; n/total n (%)	71/300 (23.7)	61/299 (20.4)
Fibrinolysis < 24 h before randomization; n/total (%)	28/301 (9.3)	20/299 (6.7)
STEMI/LBBB; n/total (%)	200/300 (66.7)	212/298 (71.1)
NSTEMI; n/total (%)	96/300 (32.0)	81/298 (27.2)
Resuscitation before randomization; n/total (%)	127/301 (42.2%)	143/299 (47.8)
Signs of impaired organ perfusion; n/total (%)		
Altered mental status	215/300 (71.7)	232/299 (77.6)
Cold, clammy skin and extremities	257/300 (85.7)	245/299 (81.9)
Oliguria	90/300 (30.0)	99/299 (33.1)
Serum lactate >2.0 mmol/l	226/300 (75.3)	218/298 (73.2)
Creatinine clearance (ml/min); median (IQR)	60.7 (43.4-86.6)	56.8 (39.7-78.1)
Infarct related artery; n/total (%)		
LAD	132/293 (45.1)	121/293 (41.3)
LCX	55/293 (18.8)	57/293 (19.5)
RCA	73/293 (24.9)	79/293 (27.0)
Left main	26/293 (8.9)	28/293 (9.6)
Bypass graft	7/293 (2.4)	8/293 (2.7)
Multivessel disease; n/total (%)	235/296 (79.4)	228/293 (77.9)
Left ventricular ejection fraction (%); median (IQR)	35 (25-45)	35 (25-45)

Results

Treatment + Process of Care Outcomes

IABP SHOCK II
RANDOMIZED CLINICAL TRIAL

Variable	IABP (n=301)	Control (n=299)	p
Primary PCI; n/total (%)	287/301 (95.3)	288/299 (96.3)	0.55
Stent implanted; n/total (%)	273/301 (90.7)	266/299 (89.0)	0.48
Drug-eluting stent; n/total (%)	126/301 (41.9)	123/299 (41.1)	0.86
Immediate PCI of non-culprit lesions; n/total (%)	90/301 (29.9)	81/299 (27.1)	0.45
Immediate bypass surgery; n/total (%)	8/301 (2.7)	10/299 (3.3)	0.62
Staged bypass surgery; n/total (%)	3/301 (1.0)	4/299 (1.3)	0.72
Active left ventricular assist device; n/total (%)	11/301 (3.7)	22/299 (7.4)	0.053
Mild hypothermia; n/total (%)	106/301 (35.2)	120/299 (40.1)	0.21
Mechanical ventilation; n/total (%)	240/301 (79.7)	252/299 (84.3)	0.15
Mechanical ventilation duration (days); median (IQR)	3.0 (1.0-8.0)	3.0 (1.0-8.0)	0.44
ICU treatment (days); median (IQR)	6.0 (3.0-12.0)	6.0 (3.0-13.0)	0.34
Renal replacement therapy; n/total (%)	62/301 (20.6)	47/299 (15.7)	0.12
Catecholamines (µg/kg per minute); median (IQR)			
Dopamine	4.1 (2.9-7.7)	4.2 (3.6-8.3)	0.76
Norepinephrine	0.3 (0.1-1.2)	0.4 (0.1-1.1)	0.73
Epinephrine	0.3 (0.1-1.3)	0.3 (0.2-1.4)	0.59
Dobutamine	10.2 (4.9-20.6)	9.0 (4.8-17.6)	0.25
Duration of catecholamines (days), median (IQR)	3.0 (1.0-5.0)	3.0 (1.0-6.0)	0.81
Time - hemodynamic stabilization (days); median (IQR)	3.0 (1.0-5.0)	3.0 (1.0-6.0)	0.50

Results

Simplified Acute Physiology Score-II



Results

Renal Function (eGFR)



Results

Serum Lactate



Results

Inflammatory Reaction (CRP)



Results

Primary Study Endpoint (30-Day Mortality)



Results

Subgroups (30-Day Mortality)

IABP SHOCK II RANDOMIZED CLINICAL TRIAL

Baseline Variable	N	30-Day Mortality (%) IABP	30-Day Mortality (%) Control	Relative Risk (95% CI)	P-Value for Interaction
Female	187	44.4	43.2	1.03 (0.74-1.43)	0.61
Male	411	37.3	40.5	0.92 (0.72-1.18)	
Age <50 years	70	19.4	44.1	0.44 (0.21-0.95)	0.09
Age 50-75 years	334	34.6	36.5	0.95 (0.71-1.27)	
Age >75 years	194	53.7	40.0	1.07 (0.81-1.41)	
Diabetes	195	42.9	46.7	0.92 (0.67-1.26)	0.82
No diabetes	399	37.2	38.9	0.96 (0.74-1.23)	
Hypertension	410	42.9	40.4	1.06 (0.84-1.34)	0.05
No hypertension	183	28.9	43.0	0.67 (0.45-1.01)	
STEMI/LBBB	412	41.0	42.9	0.96 (0.77-1.21)	0.76
NSTEMI	177	37.5	38.3	0.98 (0.67-1.43)	
Anterior STEMI	216	35.4	43.7	0.81 (0.58-1.13)	0.14
Non-anterior STEMI	196	48.3	42.2	1.16 (0.85-1.57)	
Previous infarction	131	47.9	33.3	1.44 (0.93-2.21)	0.04
No previous infarction	466	37.3	43.3	0.86 (0.69-1.07)	
Hypothermia	226	48.1	44.2	1.09 (0.82-1.44)	0.31
No hypothermia	372	35.1	39.3	0.89 (0.68-1.16)	
Blood pressure <80 mmHg	161	50.7	46.4	1.09 (0.79-1.50)	0.76
Blood pressure ≥80 mmHg	432	35.9	39.2	0.92 (0.72-1.17)	



Safety

	IABP (n=300)	Control (n=298)	P
Stroke in-hospital n/total (%)	2/300 (0.7)	5/298 (1.7)	0.28
GUSTO bleeding; n/total n (%)			
Life-threatening/severe	10/300 (3.3)	13/298 (4.4)	0.51
Moderate	52/300 (17.3)	49/298 (16.4)	0.77
Peripheral ischemic complication requiring intervention; n/total n (%)	13/300 (4.3)	10/298 (3.4)	0.53
Sepsis; n/total n (%)	47/300 (15.7)	61/298 (20.5)	0.15

Randomized Studies in Cardiogenic Shock



Trial	Follow-up	n/N	n/N	Relative Risk 95% CI	Relative Risk 95% CI
Revascularization (PCI/CABG)					
SHOCK	1-year	76/152	83/149		0.80 (0.66;0.98)
SMASH	30 days	22/32	18/23		0.87 (0.66;1.29)
Total		**103/184**	**117/172**		**0.82 (0.70;0.98)**
Catecholamines					
SOAP II (CS Subgroup)	28 days	64/145	50/135		0.75 (0.55;0.93)
Glycoprotein IIb/IIIa-Inhibitors					
PRAGUE-7	In-hospital	15/40	13/40		1.15 (0.59;2.27)
NO Synthase Inhibitors					
TRIUMPH	30 days	97/201	76/180		1.14 (0.91;1.45)
SHOCK-2	30 days	24/59	7/20		1.16 (0.59;2.69)
Cotter et al	30 days	4/15	10/15		0.40 (0.13;1.05)
Total		**125/275**	**93/215**		**1.05 (0.85;1.29)**
IABP					
IABP-SHOCK I	30 days	7/19	6/21		1.28 (0.45;3.72)
IABP-SHOCK II	30 days	119/300	123/298		0.96 (0.79;1.17)
Total		**126/319**	**129/319**		**0.98 (0.81;1.18)**
LVAD					
Thiele et al	30 days	9/21	9/20		0.95 (0.48;1.90)
Burkhoff et al	30 days	9/19	5/14		1.33 (0.57-3.10)
Seyfarth et al	30 days	6/13	6/13		1.00 (0.44-2.29)
Total		**24/53**	**20/47**		**1.06 (0.68-1.66)**



Updated from Thiele et al. Eur Heart J 2010,31:1828-1835

Summary + Conclusions

- IABP support in cardiogenic shock is safe without significant inherent complications.
- However, IABP support did not reduce 30-day mortality in this large, randomized, multicenter trial in cardiogenic shock patients complicating myocardial infarction undergoing early revascularization.
- The primary study endpoint results are supported by a lack of benefit in secondary endpoints.

Acknowledgement and Thank You

IABP-SHOCK II Investigators from 37 German Sites

Steering Committee

H. Thiele (Chair)
G. Schuler
K. Werdan
U. Zeymer

Funding

DFG
DSHF
DGK
ALKK
University of Leipzig – Heart Center
Maquet Cardiovascular
Teleflex Medical

DSMB

J. Haerting (Chair)
F. Follath
K. Huber
B. Maisch

Study Sites

Leipzig; H. Thiele, G. Schuler, S. Desch, G. Fuernau, I. Eitel, S. de Waha, S. Wetzel, T. Pausewang, A. Leuschner
Bad Krozingen: F.-J. Neumann, M. Ferenc
Langen. H.-G. Olbrich, H.-B. Hopf
Munich German Heart Center: J. Hausleiter, A. de Waha, M. Orban, C. Lennerz, M. Seyfarth
Bad Segeberg: G. Richardt, B. Schwarz, M. Abdel-Wahab, R. Toelg, V. Geist, M. Bahnsen-Maaß
Heilbronn: M. Hennersdorf, U. Rieman, J. Graf, A. Kuhn, D. Scharpf
Greifswald: K. Empen. S. Felix
Halle (Saale): K. Werdan, H. Ebelt, A. Schlitt, M. Buerke
Bremen: R. Hambrecht, E. Fiehn, A. Fach
Ludwigshafen: U. .Zeymer, A. K. Gitt, B. Mark, R.Winkler
Bad Berka: B. Lauer, J. Fuhrmann
Homburg/Saar: M. Böhm, A. Link
Jena: H.R. Figulla, M. Ferrari, C. Jung, S. Utschig
Lübeck: V. Kurowski, S. Wolfrum, P.W. Radke, H. Schunkert
Hennigsdorf: H.-H. Minden
Magdeburg: R. C. Braun-Dullaeus, F. Walz, A. Schmeißer
Cottbus – Heart Center: J. Krülls-Münch, K. Rochor
Dresden: R. H. Strasser, G. Simonis
Würzburg: S. Maier, G. Ertl
Munich – Neuperlach: H. Mudra, M. Hug
Regensburg: P. Bomba, P. Sick
Berlin – Banjamin Franklin: C. Tschöpe, H.-P. Schutlheiss
Berlin – Vivantes am Urban: H. Roth, D. Andresen
Cottbus – Carl-Thiem-Klinikum: C. Kurek, J. Krülls-Münch
Rostock: C. Nienaber, H. Ince, H. Schneider
Bad Nauheim: C. Hamm, H. Möllmann
Erfurt: H. Lapp
Berlin – Charité Mitte: G. Baumann, F. Knebel
Munich – Großhadern: W. Franz
Berlin – Vivantes AVK: H. Schühlen, L. U. Sttracke
Weiden: R. H. Schwinger, H. Bäuml
Fulda: V. Schächinger
Essen: M. Lichtenberg
Unna: D. Gießmann
Merseburg: R. Prondzinsky
Detmold: U. Tebbe
Villingen-Schwenningen: R. Birkemeyer

CEC

H. Thiele
U. Zeymer

CRO IHF Ludwigshafen

S. Schneider (Statistics chair)
T. Oarrak (Statistics)
U. Zeymer
K. Vonderschmitt
Z. Alkisoglu
S. Frey
B. Messemer

www.nejm.org

IABP SHOCK II RANDOMIZED CLINICAL TRIAL

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock

Holger Thiele, M.D., Uwe Zeymer, M.D., Franz-Josef Neumann, M.D., Miroslaw Ferenc, M.D., Hans-Georg Olbrich, M.D., Jörg Hausleiter, M.D., Gert Richardt, M.D., Marcus Hennersdorf, M.D., Klaus Empen, M.D., Georg Fuernau, M.D., Steffen Desch, M.D., Ingo Eitel, M.D., Rainer Hambrecht, M.D., Jörg Fuhrmann, M.D., Michael Böhm, M.D., Henning Ebelt, M.D., Steffen Schneider, Ph.D., Gerhard Schuler, M.D., and Karl Werdan, M.D., for the IABP-SHOCK II Trial Investigators*